Interactions between cannabis and schizophrenia in humans and rodents

References

Ameri, A. (1999). The effects of cannabinoids on the brain. Prog. Neurobiol. 58, 315–348.10.1016/S0301-0082(98)00087-2Search in Google Scholar PubMed

Appels, M.C., Sitskoorn, M.M., Vollema, M.G., and Kahn, R.S. (2004). Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders. Schizophr. Bull. 30, 781–790.10.1093/oxfordjournals.schbul.a007131Search in Google Scholar PubMed

Appiah-Kusi, E., Leyden, E., Parmar, S., Mondelli, V., McGuire, P., and Bhattacharyya, S. (2015). Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychol. Med. 46, 1–19.10.1017/S0033291715001786Search in Google Scholar PubMed

Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., and Moffitt, T.E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br. Med. J. 325, 1212–1213.10.1136/bmj.325.7374.1212Search in Google Scholar PubMed PubMed Central

Awad, A.G. and Voruganti, L.L. (2015). Revisiting the ‘self-medication’ hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior. Ther. Adv. Psychopharmacol. 5, 172–178.10.1177/2045125315583820Search in Google Scholar PubMed PubMed Central

Bailey, E.L. and Swallow, B.L. (2004). The relationship between cannabis use and schizotypal symptoms. Eur. Psychiat. 19, 113–114.10.1016/j.eurpsy.2003.12.001Search in Google Scholar PubMed

Barkus, E. and Lewis, S. (2008). Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol. Med. 38, 1267–1276.10.1017/S0033291707002619Search in Google Scholar PubMed

Barkus, E., Morrison, P.D., Vuletic, D., Dickson, J.C., Ell, P.J., Pilowsky, L.S., Brenneisen, R., Holt, D.W., Powell, J., Kapur, S., et al. (2011). Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J. Psychopharmacol. 25, 1462–1468.10.1177/0269881110382465Search in Google Scholar PubMed

Barnes, T.R., Mutsatsa, S.H., Hutton, S.B., Watt, H.C., and Joyce, E.M. (2006). Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiat. 188, 237–242.10.1192/bjp.bp.104.007237Search in Google Scholar PubMed

Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O’Carroll, C.M., Seal, M., Allen, P., et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764–774.10.1038/npp.2009.184Search in Google Scholar PubMed PubMed Central

Bornstein, R.A., Nasrallah, H.A., Olson, S.C., Coffman, J.A., Torello, M., and Schwarzkopf, S.B. (1990). Neuropsychological deficit in schizophrenic subtypes: paranoid, nonparanoid, and schizoaffective subgroups. Psychiat. Res. 31, 15–24.10.1016/0165-1781(90)90104-DSearch in Google Scholar

Calvigioni, D., Hurd, Y.L., Harkany, T., and Keimpema, E. (2014). Neuronal substrates and functional consequences of prenatal cannabis exposure. Eur. Child. Adoles. Psy. 23, 931–941.10.1007/s00787-014-0550-ySearch in Google Scholar

Cannon, M. and Murray, R.M. (1998). Neonatal origins of schizophrenia. Arch. Dis. Child. 78, 1–3.10.1136/adc.78.1.1Search in Google Scholar PubMed

Cardno, A.G. and Owen, M.J. (2014). Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. Schizophr. Bull. 40, 504–515.10.1093/schbul/sbu016Search in Google Scholar PubMed

Chambers, R.A. and Self, D.W. (2002). Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 27, 889–905.10.1016/S0893-133X(02)00365-2Search in Google Scholar PubMed

Clausen, L., Hjorthoj, C.R., Thorup, A., Jeppesen, P., Petersen, L., Bertelsen, M., and Nordentoft, M. (2013). Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol. Med. 44, 117–126.10.1017/S0033291713000433Search in Google Scholar PubMed

Cohen, M., Solowij, N., and Carr, V. (2008). Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust. N. Z. J. Psychiat. 42, 357–368.10.1080/00048670801961156Search in Google Scholar PubMed

Cougnard, A., Marcelis, M., Myin-Germeys, I., De Graaf, R., Vollebergh, W., Krabbendam, L., Lieb, R., Wittchen, H.U., Henquet, C., Spauwen, J., et al. (2007). Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychol. Med. 37, 513–527.10.1017/S0033291706009731Search in Google Scholar PubMed

D’Souza, D.C., Abi-Saab, W.M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T.B., and Krystal, J.H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiat. 57, 594–608.10.1016/j.biopsych.2004.12.006Search in Google Scholar PubMed

Davis, G.P., Compton, M.T., Wang, S., Levin, F.R., and Blanco, C. (2013). Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr. Res. 151, 197–202.10.1016/j.schres.2013.10.018Search in Google Scholar PubMed PubMed Central

De Petrocellis, L. and Di Marzo, V. (2010). Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmun. Pharmacol. 5, 103–121.10.1007/s11481-009-9177-zSearch in Google Scholar

Dean, B., Sundram, S., Bradbury, R., Scarr, E., and Copolov, D. (2001). Studies on [³H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9–15.10.1016/S0306-4522(00)00552-2Search in Google Scholar PubMed

Deas, D. and Brown, E.S. (2006). Adolescent substance abuse and psychiatric comorbidities. J. Clin. Psychiat. 67, e02.10.4088/JCP.0706e02Search in Google Scholar

Degenhardt, L., Hall, W., and Lynskey, M. (2003). Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depen. 71, 37–48.10.1016/S0376-8716(03)00064-4Search in Google Scholar

Degenhardt, L., Tennant, C., Gilmour, S., Schofield, D., Nash, L., Hall, W., and McKay, D. (2007). The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol. Med. 37, 927–934.10.1017/S0033291707009956Search in Google Scholar PubMed

DeRosse, P., Kaplan, A., Burdick, K.E., Lencz, T., and Malhotra, A.K. (2010). Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr. Res. 120, 95–100.10.1016/j.schres.2010.04.007Search in Google Scholar PubMed

Dickey, C.C., McCarley, R.W., Niznikiewicz, M.A., Voglmaier, M.M., Seidman, L.J., Kim, S., and Shenton, M.E. (2005). Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder. Schizophr. Res. 78, 297–308.10.1016/j.schres.2005.05.016Search in Google Scholar PubMed

Ehrenreich, H., Rinn, T., Kunert, H.J., Moeller, M.R., Poser, W., Schilling, L., Gigerenzer, G., and Hoehe, M.R. (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl.) 142, 295–301.10.1007/s002130050892Search in Google Scholar PubMed

Emrich, H.M., Leweke, F.M., and Schneider, U. (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol. Biochem. Behav. 56, 803–807.10.1016/S0091-3057(96)00426-1Search in Google Scholar PubMed

Esterberg, M.L., Goulding, S.M., McClure-Tone, E.B., and Compton, M.T. (2009). Schizotypy and nicotine, alcohol, and cannabis use in a non-psychiatric sample. Addict. Behav. 34, 374–379.10.1016/j.addbeh.2008.11.007Search in Google Scholar PubMed

Fadda, P., Robinson, L., Fratta, W., Pertwee, R.G., and Riedel, G. (2004). Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47, 1170–1179.10.1016/j.neuropharm.2004.08.009Search in Google Scholar PubMed

Fanous, A.H., Neale, M.C., Gardner, C.O., Webb, B.T., Straub, R.E., O’Neill, F.A., Walsh, D., Riley, B.P., and Kendler, K.S. (2007). Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. Mol. Psychiatr. 12, 958–965.10.1038/sj.mp.4001996Search in Google Scholar PubMed

Foti, D.J., Kotov, R., Guey, L.T., and Bromet, E.J. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am. J. Psychiat. 167, 987–993.10.1176/appi.ajp.2010.09020189Search in Google Scholar PubMed PubMed Central

Fowler, I.L., Carr, V.J., Carter, N.T., and Lewin, T.J. (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophr. Bull. 24, 443–455.10.1093/oxfordjournals.schbul.a033339Search in Google Scholar PubMed

Gallinat, J., Rentzsch, J., and Roser, P. (2012). Neurophysiological effects of cannabinoids: implications for psychosis research. Curr. Pharm. Des. 18, 4938–4949.10.2174/138161212802884582Search in Google Scholar PubMed

Gallo, A., Bouchard, C., and Rompre, P.P. (2014). Animals with a schizophrenia-like phenotype are differentially sensitive to the motivational effects of cannabinoid agonists in conditioned place preference. Behav. Brain Res. 268, 202–212.10.1016/j.bbr.2014.04.020Search in Google Scholar PubMed

Gaoni, Y. and Mechoulam, R. (1971). The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J. Am. Chem. Soc. 93, 217–224.10.1021/ja00730a036Search in Google Scholar PubMed

Giuffrida, A., Leweke, F.M., Gerth, C.W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J., and Piomelli, D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108–2114.10.1038/sj.npp.1300558Search in Google Scholar PubMed

Glassman, A.H. (1993). Cigarette smoking: implications for psychiatric illness. Am. J. Psychiat. 150, 546–553.10.1176/ajp.150.4.546Search in Google Scholar PubMed

Gorynia, I., Schwaiger, M., and Heinz, A. (2014). Effects of eye dominance (left vs. right) and cannabis use on intermanual coordination and negative symptoms in schizophrenia patients. Eur. Arch. Psy. Clin. N. 264, 683–695.10.1007/s00406-014-0503-ySearch in Google Scholar PubMed

Goswami, S., Mattoo, S.K., Basu, D., and Singh, G. (2004). Substance-abusing schizophrenics: do they self-medicate? Am. J. Addict. 13, 139–150.10.1080/10550490490435795Search in Google Scholar

Green, A.I., Tohen, M.F., Hamer, R.M., Strakowski, S.M., Lieberman, J.A., Glick, I., Clark, W.S., and HGDH Research Group (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 66, 125–135.10.1016/j.schres.2003.08.001Search in Google Scholar PubMed

Habets, P., Marcelis, M., Gronenschild, E., Drukker, M., and van Os, J. (2011). Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol. Psychiat. 69, 487–494.10.1016/j.biopsych.2010.08.010Search in Google Scholar

Harley, M., Kelleher, I., Clarke, M., Lynch, F., Arseneault, L., Connor, D., Fitzpatrick, C., and Cannon, M. (2010). Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol. Med. 40, 1627–1634.10.1017/S0033291709991966Search in Google Scholar PubMed

Harrison, P.J. and Eastwood, S.L. (2001). Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 11, 508–519.10.1002/hipo.1067Search in Google Scholar PubMed

Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H.U., and Van Os, J. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br. Med. J. 330, 11.10.1136/bmj.38267.664086.63Search in Google Scholar

Hickman, M., Vickerman, P., Macleod, J., Kirkbride, J., and Jones, P.B. (2007). Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction 102, 597–606.10.1111/j.1360-0443.2006.01710.xSearch in Google Scholar PubMed

Houston, J.E., Murphy, J., Adamson, G., Stringer, M., and Shevlin, M. (2008). Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr. Bull. 34, 580–585.10.1093/schbul/sbm127Search in Google Scholar PubMed

Hutchings, D.E. and Dow-Edwards, D. (1991). Animal models of opiate, cocaine, and cannabis use. Clin. Perinatol. 18, 1–22.10.1016/S0095-5108(18)30531-1Search in Google Scholar PubMed

Ilan, A.B., Gevins, A., Coleman, M., ElSohly, M.A., and de Wit, H. (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav. Pharmacol. 16, 487–496.10.1097/00008877-200509000-00023Search in Google Scholar PubMed

Iseger, T.A. and Bossong, M.G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr. Res. 162, 153–161.10.1016/j.schres.2015.01.033Search in Google Scholar PubMed

Jockers-Scherübl, M.C., Wolf, T., Radzei, N., Schlattmann, P., Rentzsch, J., de Castro, A.G.C., and Kühl, K.P. (2007). Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog. Neuropsychopharmacol. Biol. Psychiat. 31, 1054–1063.10.1016/j.pnpbp.2007.03.006Search in Google Scholar PubMed

Khandaker, G.M., Barnett, J.H., White, I.R., and Jones, P.B. (2011). A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophr. Res. 132, 220–227.10.1016/j.schres.2011.06.017Search in Google Scholar PubMed PubMed Central

Koethe, D., Hoyer, C., and Leweke, F.M. (2009). The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl.) 206, 551–561.10.1007/s00213-009-1591-7Search in Google Scholar PubMed

Kohen, D. (2004). Diabetes mellitus and schizophrenia: historical perspective. Br. J. Psychiat. (Suppl.) 47, S64–S66.10.1192/bjp.184.47.s64Search in Google Scholar PubMed

Konings, M., Stefanis, N., Kuepper, R., De Graaf, R., Ten Have, M., Van Os, J., Bakoula, C., and Henquet, C. (2012). Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol. Med. 42, 149–159.10.1017/S0033291711000973Search in Google Scholar PubMed

Koola, M.M., McMahon, R.P., Wehring, H.J., Liu, F., Mackowick, K.M., Warren, K.R., Feldman, S., Shim, J.C., Love, R.C., and Kelly, D.L. (2012). Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J. Psychiatr. Res. 46, 987–993.10.1016/j.jpsychires.2012.04.019Search in Google Scholar PubMed PubMed Central

Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M., and Miettunen, J. (2009). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr. Bull. 36, 1115–1130.10.1093/schbul/sbp031Search in Google Scholar PubMed PubMed Central

Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M., and Miettunen, J. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr. Bull. 36, 1115–1130.10.1093/schbul/sbp031Search in Google Scholar PubMed

Langer, O. and Halldin, C. (2002). PET and SPET tracers for mapping the cardiac nervous system. Eur. J. Nucl. Med. Mol. Imaging 29, 416–434.10.1007/s002590100640Search in Google Scholar PubMed

Large, M., Sharma, S., Compton, M.T., Slade, T., and Nielssen, O. (2011). Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch. Gen. Psychiat. 68, 555–561.10.1001/archgenpsychiatry.2011.5Search in Google Scholar

Leroy, S., Griffon, N., Bourdel, M.C., Olie, J.P., Poirier, M.F., and Krebs, M.O. (2001). Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet. 105, 749–752.10.1002/ajmg.10038Search in Google Scholar PubMed

Leweke, F.M., Giuffrida, A., Wurster, U., Emrich, H.M., and Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665–1669.10.1097/00001756-199906030-00008Search in Google Scholar PubMed

Leweke, F.M., Giuffrida, A., Koethe, D., Schreiber, D., Nolden, B.M., Kranaster, L., Neatby, M.A., Schneider, M., Gerth, C.W., Hellmich, M., et al. (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 94, 29–36.10.1016/j.schres.2007.04.025Search in Google Scholar PubMed

Linszen, D.H., Dingemans, P.M., and Lenior, M.E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiat. 51, 273–279.10.1001/archpsyc.1994.03950040017002Search in Google Scholar

MacLean, K.I. and Littleton, J.M. (1977). Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol. Eur. J. Pharmacol. 41, 171–182.10.1016/0014-2999(77)90206-0Search in Google Scholar PubMed

Maki, P., Veijola, J., Jones, P.B., Murray, G.K., Koponen, H., Tienari, P., Miettunen, J., Tanskanen, P., Wahlberg, K.E., Koskinen, J., et al. (2005). Predictors of schizophrenia – a review. Br. Med. Bull. 73–74, 1–15.10.1093/bmb/ldh046Search in Google Scholar PubMed

Malaspina, D., Owen, M.J., Heckers, S., Tandon, R., Bustillo, J., Schultz, S., Barch, D.M., Gaebel, W., Gur, R.E., Tsuang, M., et al. (2013). Schizoaffective disorder in the DSM-5. Schizophr. Res. 150, 21–25.10.1016/j.schres.2013.04.026Search in Google Scholar PubMed

Malone, D.T., Hill, M.N., and Rubino, T. (2010). Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br. J. Pharmacol. 160, 511–522.10.1111/j.1476-5381.2010.00721.xSearch in Google Scholar PubMed PubMed Central

Manrique-Garcia, E., Zammit, S., Dalman, C., Hemmingsson, T., Andreasson, S., and Allebeck, P. (2012). Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol. Med. 42, 1321–1328.10.1017/S0033291711002078Search in Google Scholar PubMed

Margolese, H.C., Malchy, L., Negrete, J.C., Tempier, R., and Gill, K. (2004). Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 67, 157–166.10.1016/S0920-9964(02)00523-6Search in Google Scholar PubMed

Mata, I., Rodriguez-Sanchez, J.M., Pelayo-Teran, J.M., Perez-Iglesias, R., Gonzalez-Blanch, C., Ramirez-Bonilla, M., Martinez-Garcia, O., Vazquez-Barquero, J.L., and Crespo-Facorro, B. (2008). Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol. Med. 38, 1257–1266.10.1017/S0033291707002218Search in Google Scholar PubMed

McCreadie, R.G. and Kelly, C. (2000). Patients with schizophrenia who smoke. Private disaster, public resource. Br. J. Psychiat. 176, 109.10.1192/bjp.176.2.109Search in Google Scholar

McEvoy, J.P., Meyer, J.M., Goff, D.C., Nasrallah, H.A., Davis, S.M., Sullivan, L., Meltzer, H.Y., Hsiao, J., Stroup, T.S., and Lieberman, J.A. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80, 19–32.10.1016/j.schres.2005.07.014Search in Google Scholar PubMed

McGee, R., Williams, S., Poulton, R., and Moffitt, T. (2000). A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction 95, 491–503.10.1046/j.1360-0443.2000.9544912.xSearch in Google Scholar PubMed

Mizrahi, R., Kenk, M., Suridjan, I., Boileau, I., George, T.P., McKenzie, K., Wilson, A.A., Houle, S., and Rusjan, P. (2014). Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39, 1479–1489.10.1038/npp.2013.347Search in Google Scholar PubMed

Moghaddam, B. and Krystal, J.H. (2003). The neurochemistry of schizophrenia. Schizophrenia. S.R. Hirsch and D.R. Weinberger, eds. (Massachusetts: Blackwell Science), pp. 349–364.10.1002/9780470987353.ch19Search in Google Scholar

Moore, T.H., Zammit, S., Lingford-Hughes, A., Barnes, T.R., Jones, P.B., Burke, M., and Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319–328.10.1016/S0140-6736(07)61162-3Search in Google Scholar PubMed

Morgan, C.J. and Curran, H.V. (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiat. 192, 306–307.10.1192/bjp.bp.107.046649Search in Google Scholar PubMed

Morgan, C.J., Page, E., Schaefer, C., Chatten, K., Manocha, A., Gulati, S., Curran, H.V., Brandner, B., and Leweke, F.M. (2013). Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br. J. Psychiat. 202, 381–382.10.1192/bjp.bp.112.121178Search in Google Scholar PubMed

Morrison, P.D. and Stone, J.M. (2011). Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum. Psychopharmacol. 26, 77–80.10.1002/hup.1166Search in Google Scholar PubMed

Mortensen, P.B. and Juel, K. (1993). Mortality and causes of death in first admitted schizophrenic patients. Br. J. Psychiat. 163, 183–189.10.1192/bjp.163.2.183Search in Google Scholar PubMed

Muller-Vahl, K.R. and Emrich, H.M. (2008). Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev. Neurother. 8, 1037–1048.10.1586/14737175.8.7.1037Search in Google Scholar PubMed

Najolia, G.M., Buckner, J.D., and Cohen, A.S. (2012). Cannabis use and schizotypy: the role of social anxiety and other negative affective states. Psychiat. Res. 200, 660–668.10.1016/j.psychres.2012.07.042Search in Google Scholar PubMed

Negrete, J.C., Knapp, W.P., Douglas, D.E., and Smith, W.B. (1986). Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol. Med. 16, 515–520.10.1017/S0033291700010278Search in Google Scholar PubMed

Pertwee, R.G. (2006). Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 147, S163–S171.10.1038/sj.bjp.0706406Search in Google Scholar PubMed PubMed Central

Pope, H.G., Jr., Gruber, A.J., and Yurgelun-Todd, D. (2001). Residual neuropsychologic effects of cannabis. Curr. Psychiat. Rep. 3, 507–512.10.1007/s11920-001-0045-7Search in Google Scholar PubMed

Potvin, S., Joyal, C.C., Pelletier, J., and Stip, E. (2008). Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr. Res. 100, 242–251.10.1016/j.schres.2007.04.022Search in Google Scholar PubMed

Rabin, R.A., Zakzanis, K.K., and George, T.P. (2011). The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr. Res. 128, 111–116.10.1016/j.schres.2011.02.017Search in Google Scholar PubMed

Radek, R.J., Miner, H.M., Bratcher, N.A., Decker, M.W., Gopalakrishnan, M., and Bitner, R.S. (2006). Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacology (Berl.) 187, 47–55.10.1007/s00213-006-0394-3Search in Google Scholar PubMed

Radhakrishnan, R., Wilkinson, S.T., and D’Souza, D.C. (2014). Gone to pot – a review of the association between cannabis and psychosis. Front. Psychiatry 5, 54.10.3389/fpsyt.2014.00054Search in Google Scholar PubMed PubMed Central

Ramaekers, J.G., Moeller, M.R., van Ruitenbeek, P., Theunissen, E.L., Schneider, E., and Kauert, G. (2006). Cognition and motor control as a function of Δ9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depen. 85, 114–122.10.1016/j.drugalcdep.2006.03.015Search in Google Scholar PubMed

Realini, N., Rubino, T., and Parolaro, D. (2009). Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol. Res. 60, 132–138.10.1016/j.phrs.2009.03.006Search in Google Scholar PubMed

Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., and Goodwin, F.K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. J. Am. Med. Assoc. 264, 2511–2518.10.1001/jama.1990.03450190043026Search in Google Scholar

Rentzsch, J., Buntebart, E., Stadelmeier, A., Gallinat, J., and Jockers-Scherubl, M.C. (2011). Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophr. Res. 130, 222–227.10.1016/j.schres.2011.05.011Search in Google Scholar PubMed

Rey, J.M., Sawyer, M.G., Raphael, B., Patton, G.C., and Lynskey, M. (2002). Mental health of teenagers who use cannabis. Results of an Australian survey. Br. J. Psychiat. 180, 216–221.10.1192/bjp.180.3.216Search in Google Scholar PubMed

Rezvani, A.H., Tizabi, Y., Getachew, B., Hauser, S.R., Caldwell, D.P., Hunter, C., and Levin, E.D. (2008). Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats. Prog. Neuropsychopharmacol. Biol. Psychiat. 32, 1030–1040.10.1016/j.pnpbp.2008.01.018Search in Google Scholar PubMed

Ringen, P.A., Lagerberg, T.V., Birkenaes, A.B., Engn, J., Faerden, A., Jonsdottir, H., Nesvåg, R., Friis, S., Opjordsmoen, S., Larsen, F., et al. (2008). Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol. Med. 38, 1241–1249.10.1017/S003329170700236XSearch in Google Scholar PubMed

Robson, P.J., Guy, G.W., Di Marzo, V. (2014). Cannabinoids and schizophrenia: therapeutic prospects. Curr. Pharm. Des. 20, 2194–2204.10.2174/13816128113199990427Search in Google Scholar PubMed

Rodvelt, K.R., Kracke, G.R., Schachtman, T.R., and Miller, D.K. (2008a). Ketamine induces hyperactivity in rats and hypersensitivity to nicotine in rat striatal slices. Pharmacol. Biochem. Behav. 91, 71–76.10.1016/j.pbb.2008.06.012Search in Google Scholar PubMed

Rodvelt, K.R., Schachtman, T.R., Kracke, G.R., and Miller, D.K. (2008b). NMDA receptor blockade augmented nicotine-evoked dopamine release from rat prefrontal cortex slices. Neurosci. Lett. 440, 319–322.10.1016/j.neulet.2008.05.106Search in Google Scholar PubMed

Rognli, E.B., Berge, J., Hakansson, A., and Bramness, J.G. (2015). Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users. Schizophr. Res. 168, 185–190.10.1016/j.schres.2015.08.032Search in Google Scholar PubMed

Rounsaville, B.J. (2007). DSM-V research agenda: substance abuse/psychosis comorbidity. Schizophr. Bull. 33, 947–952.10.1093/schbul/sbm054Search in Google Scholar PubMed PubMed Central

Rubino, T. and Parolaro, D. (2015). The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol. Psychiat. 79, 578–585.10.1016/j.biopsych.2015.07.024Search in Google Scholar PubMed

Rubino, T., Realini, N., Guidali, C., Braida, D., Capurro, V., Castiglioni, C., Cherubino, F., Romualdi, P., Candeletti, S., Sala, M., et al. (2008). Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33, 2760–2771.10.1038/sj.npp.1301664Search in Google Scholar PubMed

Schiffman, J., Nakamura, B., Earleywine, M., and LaBrie, J. (2005). Symptoms of schizotypy precede cannabis use. Psychiat. Res. 134, 37–42.10.1016/j.psychres.2005.01.004Search in Google Scholar PubMed

Schneider, M. and Koch, M. (2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760–1769.10.1038/sj.npp.1300225Search in Google Scholar PubMed

Schnell, T., Koethe, D., Daumann, J., and Gouzoulis-Mayfrank, E. (2009). The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl.) 205, 45–52.10.1007/s00213-009-1512-9Search in Google Scholar PubMed

Schnell, T., Kleiman, A., Gouzoulis-Mayfrank, E., Daumann, J., and Becker, B. (2012). Increased gray matter density in patients with schizophrenia and cannabis use: a voxel-based morphometric study using DARTEL. Schizophr. Res. 138, 183–187.10.1016/j.schres.2012.03.021Search in Google Scholar PubMed

Segev, A. and Lev-Ran, S. (2012). Neurocognitive functioning and cannabis use in schizophrenia. Curr. Pharm. Des. 18, 4999–5007.10.2174/138161212802884799Search in Google Scholar PubMed

Semple, D.M., McIntosh, A.M., and Lawrie, S.M. (2005). Cannabis as a risk factor for psychosis: systematic review. J. Psychopharmacol. 19, 187–194.10.1177/0269881105049040Search in Google Scholar PubMed

Sevy, S., Burdick, K.E., Visweswaraiah, H., Abdelmessih, S., Lukin, M., Yechiam, E., and Bechara, A. (2007). Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr. Res. 92, 74–84.10.1016/j.schres.2007.01.005Search in Google Scholar PubMed

Shrivastava, A., Johnston, M., Terpstra, K., and Bureau, Y. (2014). Cannabis and psychosis: neurobiology. Ind. J. Psychiat. 56, 8–16.10.4103/0019-5545.124708Search in Google Scholar

Skosnik, P.D., Spatz-Glenn, L., and Park, S. (2001). Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr. Res. 48, 83–92.10.1016/S0920-9964(00)00132-8Search in Google Scholar PubMed

Smart, R.G. and Ogborne, A.C. (2000). Drug use and drinking among students in 36 countries. Addict. Behav. 25, 455–460.10.1016/S0306-4603(99)00013-1Search in Google Scholar PubMed

Solowij, N. and Grenyer, B.F.S. (2002). Long-term effects of cannabis on psyche and cognition. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. F. Grotenhermen and E. Russo, eds. (New York: Haworth Press), pp. 99–311.Search in Google Scholar

Solowij, N. and Michie, P.T. (2007). Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J. Psychiatr. Neurosci. 32, 30–52.Search in Google Scholar

Spano, M.S., Fattore, L., Cadeddu, F., Fratta, W., and Fadda, P. (2013). Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology (Berl.) 225, 531–542.10.1007/s00213-012-2839-1Search in Google Scholar PubMed

Steeds, H., Carhart-Harris, R.L., and Stone, J.M. (2015). Drug models of schizophrenia. Ther. Adv. Psychopharmacol. 5, 43–58.10.1177/2045125314557797Search in Google Scholar PubMed

Stella, N. and Piomelli, D. (2001). Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425, 189–196.10.1016/S0014-2999(01)01182-7Search in Google Scholar PubMed

Stirling, J., Lewis, S., Hopkins, R., and White, C. (2005). Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 75, 135–137.10.1016/j.schres.2004.10.006Search in Google Scholar PubMed

Szutorisz, H., DiNieri, J.A., Sweet, E., Egervari, G., Michaelides, M., Carter, J.M., Ren, Y., Miller, M.L., Blitzer, R.D., and Hurd, Y.L. (2014). Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology 39, 1315–1323.10.1038/npp.2013.352Search in Google Scholar PubMed PubMed Central

Tandon, R., Keshavan, M.S., and Nasrallah, H.A. (2008). Schizophrenia, “just the facts”: what we know in 2008 part 1: overview. Schizophr. Res. 100, 4–19.10.1016/j.schres.2008.01.022Search in Google Scholar PubMed

Tantra, M., Kröcher, T., Papiol, S., Winkler, D., Röckle, I., Jatho, J., Burkhardt, H., Ronnenberg, A., Gerardy-Schahn, R., Ehrenreich, H., et al. (2014). St8sia2 deficiency plus juvenile cannabis exposure in mice synergistically affect higher cognition in adulthood. Behav. Brain Res. 275, 166–175.10.1016/j.bbr.2014.08.062Search in Google Scholar PubMed

Trezza, V., Cuomo, V., and Vanderschuren, L.J. (2008). Cannabis and the developing brain: insights from behavior. Eur. J. Pharmacol. 585, 441–452.10.1016/j.ejphar.2008.01.058Search in Google Scholar PubMed

Tsiridis, E., Lusty, P.J., Narvani, A.A., and Tsapakis, E.M. (2003). Doctors’ knowledge of exposure to ionising radiation: doctors’ exposure to ionising radiation may be cause for concern. Br. Med. J. 327, 1167.10.1136/bmj.327.7424.1167Search in Google Scholar

Tunbridge, E.M., Bannerman, D.M., Sharp, T., and Harrison, P.J. (2004). Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J. Neurosci. 24, 5331–5335.10.1523/JNEUROSCI.1124-04.2004Search in Google Scholar PubMed

Ujike, H. and Morita, Y. (2004). New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J. Pharmacol. Sci. 96, 376–381.10.1254/jphs.FMJ04003X4Search in Google Scholar PubMed

van Nimwegen, L., de Haan, L., van Beveren, N., van den Brink, W., and Linszen, D. (2005). Adolescence, schizophrenia and drug abuse: a window of vulnerability. Acta Psychiatr. Scand. (Suppl.) 427, 35–42.10.1111/j.1600-0447.2005.00543.xSearch in Google Scholar

Von Sydow, K., Lieb, R., Pfister, H., Hofler, M., Sonntag, H., and Wittchen, H.U. (2001). The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depen. 64, 347–361.10.1016/S0376-8716(01)00137-5Search in Google Scholar

Weiser, M., Reichenberg, A., Grotto, I., Yasvitzky, R., Rabinowitz, J., Lubin, G., Nahon, D., Knobler, H.Y., and Davidson, M. (2004). Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am. J. Psychiat. 161, 1219–1223.10.1176/appi.ajp.161.7.1219Search in Google Scholar PubMed

Wilkinson, S.T., Radhakrishnan, R., and D’Souza, D.C. (2014). Impact of cannabis use on the development of psychotic disorders. Curr. Addict. Rep. 1, 115–128.10.1007/s40429-014-0018-7Search in Google Scholar PubMed PubMed Central

Wobrock, T., Falkai, P., Schneider-Axmann, T., Hasan, A., Galderisi, S., Davidson, M., Kahn, R.S., Derks, E.M., Boter, H., Rybakowski, J.K., et al. (2013). Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr. Res. 147, 132–139.10.1016/j.schres.2013.03.001Search in Google Scholar PubMed

Yucel, M., Bora, E., Lubman, D.I., Solowij, N., Brewer, W.J., Cotton, S.M., Pantelis, C. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr. Bull. 38, 316–330.10.1093/schbul/sbq079Search in Google Scholar PubMed PubMed Central

Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., and Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J. 325, 1199.10.1136/bmj.325.7374.1199Search in Google Scholar PubMed PubMed Central

Zammit, S., Moore, T.H., Lingford-Hughes, A., Barnes, T.R., Jones, P.B., Burke, M., and Lewis, G. (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br. J. Psychiat. 193, 357–363.10.1192/bjp.bp.107.046375Search in Google Scholar PubMed

Zuardi, A.W., Shirakawa, I., Finkelfarb, E., and Karniol, I.G. (1982). Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology (Berl.) 76, 245–250.10.1007/BF00432554Search in Google Scholar PubMed